ICR | Bristol Myers’ autoimmune drug shows potential in lupus

Bristol Myers’ autoimmune drug shows potential in lupus

Bristol Myers Squibb’s experimental autoimmune disease drug deucravacitinib helped treat moderate-to-severe lupus in a Phase 2 trial, the company reported Wednesday. Results, which were presented at a medical conference in Denmark, showed two doses of the pill led to significantly higher response rates than did a placebo.

The oldest independent membership-led professional body for clinical researchers across the globe.